- Home
- XERS vs SBSI Comparison
XERS vs SBSI Comparison
Compare XERS & SBSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XERS | SBSI |
|---|---|---|
| Founded | 2005 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 972.0M |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | XERS | SBSI |
|---|---|---|
| Price | $6.30 | $31.77 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | $10.83 | ★ $35.33 |
| AVG Volume (30 Days) | ★ 1.6M | 69.5K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 4.42% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | 0.01 | ★ 0.78 |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $34.37 | $28.87 |
| Revenue Next Year | $22.86 | $5.82 |
| P/E Ratio | $636.50 | ★ $41.47 |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $4.30 | $26.32 |
| 52 Week High | $10.08 | $34.53 |
Technical Indicators
Market Signals| Indicator | XERS | SBSI |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 43.34 |
| Support Level | $6.26 | $31.82 |
| Resistance Level | $6.41 | $33.82 |
| Average True Range (ATR) | 0.28 | 0.95 |
| MACD | 0.00 | -0.21 |
| Stochastic Oscillator | 28.50 | 5.61 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About SBSI Southside Bancshares Inc.
Southside Bancshares Inc is a bank holding company. Through its subsidiary, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.